Description
12.5mg Retatrutide , 2.5mg cagrilintide
15mg vials
Retatrutide and Cagrilintide is a research peptide combination of a triple-agonist incretin analog and a long-acting amylin analog, supplied as a high-purity lyophilized blend for laboratory use only.
Retatrutide is a synthetic peptide analog studied in laboratory models of GIP, GLP-1, and glucagon receptor signaling. Cagrilintide is a modified 37-amino-acid amylin analog featuring structural substitutions and a fatty-acid side chain. Together they are used in controlled laboratory studies of peptide identity, stability, structure, and related biochemical pathways. Each component is typically verified by HPLC and mass spectrometry.
In laboratory and preclinical research, this pairing has been investigated for effects on metabolic and neuroendocrine signaling, including incretin-pathway activity, amylin-receptor models, appetite-regulation pathways, and energy-balance mechanisms in experimental systems. These findings are limited to research settings and do not establish approved medical use.
This material is not approved for human or veterinary use and is not intended for consumption.
Reviews
There are no reviews yet.